Tower Bridge Advisors Increases Stake in Gilead Sciences, Inc. (GILD)

Tower Bridge Advisors raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 3,779 shares of the biopharmaceutical company’s stock after purchasing an additional 3 shares during the period. Tower Bridge Advisors’ holdings in Gilead Sciences were worth $267,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of GILD. Harel Insurance Investments & Financial Services Ltd. boosted its stake in shares of Gilead Sciences by 583.3% during the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 1,400 shares during the last quarter. Dubuque Bank & Trust Co. boosted its stake in shares of Gilead Sciences by 19.4% during the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 267 shares during the last quarter. Penserra Capital Management LLC boosted its stake in shares of Gilead Sciences by 9.5% during the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 144 shares during the last quarter. Webster Bank N. A. boosted its stake in shares of Gilead Sciences by 51.7% during the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after acquiring an additional 624 shares during the last quarter. Finally, American Beacon Advisors Inc. acquired a new stake in Gilead Sciences in the 1st quarter worth about $143,000. 73.97% of the stock is currently owned by institutional investors.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the sale, the insider now directly owns 3,199,969 shares in the company, valued at $227,197,799. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total transaction of $355,300.00. Following the sale, the executive vice president now owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The disclosure for this sale can be found here. Insiders have sold 466,819 shares of company stock valued at $36,740,240 over the last 90 days. Company insiders own 1.30% of the company’s stock.

A number of brokerages have issued reports on GILD. ValuEngine raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. Vetr downgraded Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective on the stock. in a report on Monday, September 4th. Finally, Wells Fargo & Company raised their price objective on Gilead Sciences from $73.00 to $81.00 and gave the stock a “market perform” rating in a report on Wednesday, September 6th. Eleven investment analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $84.29.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 83.27 on Friday. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The company has a 50-day moving average price of $77.54 and a 200-day moving average price of $70.38. The stock has a market cap of $108.74 billion, a PE ratio of 9.04 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The business had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter last year, the company posted $3.08 earnings per share. Gilead Sciences’s quarterly revenue was down 8.2% on a year-over-year basis. Analysts anticipate that Gilead Sciences, Inc. will post $8.78 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.50%. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of international trademark & copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/tower-bridge-advisors-has-267000-stake-in-gilead-sciences-inc-gild/1603638.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

American League Once Again Dominates National League
American League Once Again Dominates National League
Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22


Leave a Reply

 
© 2006-2017 BBNS.